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Abstract: Lung adenocarcinoma is characterized by complex biology involving alterations at the genomic and protein 
expression levels. FGFR2 mutation and/or amplification are key drivers of disease progression and drug resistance 
in lung adenocarcinoma patients. These genetic alterations drive oncogenic downstream signalling due to the de-
regulated activity of the receptor. We have previously reported that wild type FGFR2 provides a binding site for which 
two proteins, Grb2 and Plcγ1, compete in a concentration-dependent manner. Metastasis and invasion ensue when 
Plcγ1 prevails on the receptor giving rise to oncogenic outcome in the absence of gene mutation/deletion. The ef-
fect of this signalling mechanism on FGFR2-driven lung adenocarcinoma has not previously been considered. In 
this study we show that fluctuation in the combinatorial expression levels of FGFR2, Grb2 and Plcγ1 modulates cell 
invasive properties, tumor formation and is linked to recurrence-free survival in 150 lung adenocarcinoma patients. 
High levels of expression of FGFR2 and Plcγ1 in a low background of Grb2 significantly correlates with poor progno-
sis. On the other hand, low levels of expression of FGFR2 and Plcγ1 in a high background of Grb2 correlates with 
favourable prognosis. This study defines the expression pattern of FGFR2, Plcγ1 and Grb2 as a novel prognostic 
marker in human lung adenocarcinoma. Thus, consideration of the Grb2 and Plcγ1-mediated mechanism of FGFR2 
regulation will enhance the therapeutic targeting of aberrant FGFR2 activity to provide the much-needed improve-
ment to the treatment regimen of this high mortality disease.
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Introduction
Lung cancer is the leading cause of neoplasia-
related mortality worldwide with 1.6 million 
deaths per year [1]. The majority of the cases 
are non-small cell lung cancer (NSCLC) which is 
split into 3 subtypes, adenocarcinoma (LUAD) 
(representing 40% of total lung cancer cases), 
squamous cell (epidermoid) carcinoma (30%) 
and large cell (undifferentiated) carcinoma 
(15%). These cases have a 5-year survival rate 
of only 15% due to late stage diagnosis, recur-
rence and metastasis [2-7]. Adopting conven-
tional treatments for LUAD, such as surgical 
resection followed by adjuvant chemotherapy, 
are limited based on the difficulties in ensuring 
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optimal benefit from therapeutic decisions 
[8-15]. As such, identifying novel biomarkers of 
disease progression would allow for better 
prognosis leading to therapeutic gain, person-
alized medical treatment and management of 
LUAD patients [16-20].
Fibroblast growth factor receptor 2 (FGFR2) is a 
cell surface receptor with a complex network of 
downstream signalling pathways fundamental 
to normal cellular processes [21]. Aberrant sig-
nalling caused by the mutation and/or amplifi-
cation of FGFR2 have been commonly observed 
in multiple cancer types like colon, gastric can-
cer and lung cancer [7, 22-26]. Constitutive 
activation of the kinase occurring in a defined 
population of LUAD patients, along with the 
tumor’s sensitivity to pan-FGFR2 inhibition 
make it a good therapeutic target, however a 
highly effective method for targeting FGFR2 
has not yet been achieved [7, 27]. Furthermore, 
increased FGFR2 expression as a drug resis-
tance mechanism make it a suitable prognostic 
marker and it has been previously reported 
that FGFR2 expression is a valuable indicative 
of LUAD clinical outcome [22, 28] yet the level 
of expression of FGFR2 binding partners and 
their role as LUAD prognostic markers in a com-
binatorial fashion have never been investi- 
gated. 
We have previously shown that under growth 
factor-deprived conditions FGFR2 function can 
be regulated by two proteins, growth factor 
receptor bound protein 2 (Grb2) and phospholi-
pase C gamma 1 (Plcγ1). These proteins com-
pete for the same proline-rich binding site on 
the C-terminus of the receptor via their Src 
homology 3 (SH3) domains in a concentration-
dependent manner [29, 30]. In cells expressing 
elevated levels of Grb2, Plcγ1 cannot be recruit-
ed to the receptor and cells maintain normal 
FGFR2-mediated functionality. However, in 
cells with depleted Grb2 concentration, Plcγ1 is 
able to bind to the receptor resulting in phos-
phorylation-independent activation of the 
lipase driving oncogenic outcomes such as cel-
lular migration and invasion [29, 30]. Two 
important questions emerge from these stud-
ies; is the combinatorial expression level of 
FGFR2, Grb2 and Plcγ1 of any clinical relevance 
in cancer patients? And will the inclusion of 
Grb2 and Plcγ1 in FGFR2 survival studies 
enhance the precision of the prognostic poten-
tial of FGFR2 expression? In this work, we 
investigate the mRNA and protein levels of 
FGFR2, Grb2 and Plcγ1 in cell lines, a xenograft 
mouse model and LUAD patients to test for 
their correlation with oncogenic behaviour and 
clinical outcome. We report that recurrence-
free survival of patients (adjusted for character-
istics, e.g. age, gender, tobacco history, adju-
vant therapy) correlates with the expression 
levels of FGFR2, Grb2 and Plcγ1 forming the 
basis for a critical combinatorial prognostic 
marker. FGFR2, Plcγ1 and Grb2 respectively 
being at high, high and low concentrations 
results in significantly poorer prognosis. 
However, with concentrations respectively 
being low, low and high, the prognosis is 
improved. The results obtained from patient 
profiles are in agreement with the markers’ 
molecular signature and functional effects in 
lung adenocarcinoma cell lines. Therefore, 
combinational data on relative expression lev-
els of these proteins provides the opportunity 
for better prognosis in patients and an improved 
understanding of the contributing factors and 
potential causes behind FGFR2 drug/inhibitor 
resistance. This allows for an informed decision 
on the choice and success rate of therapy (in 
this case adjuvant therapy).
Materials and methods
Cells 
Human embryonic kidney 293T (HEK293T) and 
human NSCLC cell lines, were maintained in 
Dulbecco’s modified Eagle’s high-glucose medi-
um (DMEM) supplemented with 10% (v/v) FBS 
and 1% antibiotic/antimycotic (Lonza) in a 
humidified incubator at 37°C with 10% CO2. 
HEK293T cells were stably transfected with a 
C-terminal GFP fusion (FGFR2-GFP) and knock-
down cells were generated by infecting cells 
with either scrambled shRNA, Grb2 shRNA or 
Plcγ1 shRNA containing lentiviral particles. 
Knockdowns were confirmed by western blot-
ting. For experimental protocols cells were 
serum starved then left untreated or stimulat-
ed with FGF9 for 30 min. Cultured cells were 
grown in 10 cm dishes, serum-starved over-
night, and left unstimulated or were stimulated 
with 20 ng/ml FGF9 (R&D Systems) for 30 min. 
Cells were lysed with HEPES lysis buffer (50 
mM HEPES, pH 7.5, 1% (v/v) IGEPAL-C630, 1 
mg/ml bacitracin, 1 mM EDTA, 10 mM NaF, 1 
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mM sodium orthovanadate, 10% (v/v) glycerol, 
50 mM NaCl, 1 mM PMSF, and Protease 
Inhibitor Cocktail Set III (EMD Millipore)). Protein 
concentration was quantified by Bradford 
assay, and 50 μg of total proteins was used for 
every assay. 
Xenograft mouse model
Adult female nude mice were injected with 1 × 
106 cells in PBS (5 mice per group). Cells used 
were stably transfected with pGL3-basic empty 
luciferase vector (Promega). Luciferase expres-
sion was confirmed by luciferase-reporter 
assay (Promega) and IVIS imaging system of 
the cell lines following addition of Luciferin 
(System Biosciences). Following tumor growth, 
Luciferin was injected in the mice according to 
the manufacturer’s protocol followed by peri-
odic quantitative imaging of tumor growth using 
IVIS. Next, mice were sacrificed, nodules were 
counted and tumors were weighed. Weights 
were averaged in each group and plotted as a 
bar graph where the standard deviation of the 
mean is denoted by error bars. 
IHC staining 
IHC staining of the TMA (MTU 951, LUC1021 
Pantomics), was carried out using Access 
Retrieval Buffer Menarini Diagnostics (Berk- 
shire UK) Plcγ1 (Cell Signalling Technology, 
D9H10 XP® Rabbit mAb #5690) diluted 1:25, 
FGFR2 (Santa Cruz Biotechnology, C-17; 
sc-122) diluted 1:250 and Grb2 (Santa Cruz 
Biotechnology, C-23) diluted 1:100. All antibod-
ies were diluted in Invitrogen antibody diluent, 
Life Technologies (Paisley UK). Detection was 
with the Menarini X-Cell Plus detection system.
Wound-healing and invasion assays 
Confluent cells seeded in a 12-well plate were 
serum starved overnight. The surface of the 
cells was then scratched with a pipette tip and 
the cells were washed with PBS. One group of 
cells was incubated in 1% serum for 6 h and 
another was stimulated with FGF9. The average 
distance traveled by the cells along the wound 
was quantified in three independent experi-
ments. The percentage of wound closure was 
calculated, averaged and normalized. Matrigel 
Invasion Chambers in two 24-well plates with 
8.0-μm pores were purchased from BD 
Biosciences. The experiment was carried out 
as previously described [29]. 
Statistical analysis
A total of 150 adenocarcinoma lung cancer 
patients (The Profiling of Resistance patterns 
and Oncogenic Signaling Pathways in Evaluation 
of Cancers of the Thorax (PROSPECT) trial) who 
did not receive neo-adjuvant therapy were 
included in the analysis. Patient characteristics 
and clinical outcomes are summarized using 
descriptive statistics, including mean (SD) and 
median (minimum, maximum) for continuous 
variables and frequency (%) for categorical vari-
ables. Wilcoxon rank-sum test or Kruskal-Wallis 
test was used to compare differences in con-
tinuous variables between groups. Chi-square 
test or Fisher’s exact test was used to compare 
differences in categorical variables between 
groups. Overall survival (OS) was defined as the 
time interval from surgery to the time of death 
or last contact and recurrence-free survival 
(RFS) was defined as the time interval from sur-
gery to the time of recurrence or last contact. 
Both OS and RFS were censored at 60 months 
if a patient was alive or died beyond 60 months 
for OS or if a patient was known to be recur-
rence-free at 5 years or had recurrence after 5 
years for RFS. Kaplan-Meier Method and Cox-
proportional hazards regression analyses were 
conducted on OS and RFS. For the K-M curves 
we used the median as a cut-off point and the 
binary cut-off points of biomarkers were also 
identified using a recursive partitioning algo-
rithm (rpart function in R) in which a cut-off 
point is determined for each predictor variable 
such that resulting subgroups are the most dif-
ferent in their RFS. A P value of less than 0.05 
indicated a statistical significance. SAS 9.3 
(SAS Institute Inc. Cary. NC) was used for data 
analysis.
Results
Protein expression levels of FGFR2, Grb2 and 
Plcγ1 modulate tumor growth in a xenograft 
mouse model
Prior to investigating the role of FGFR2, Grb2 
and Plcγ1 as disease prognostic markers, we 
tested their ability to modulate tumor growth 
and progression in a xenograft mouse model. 
We utilized the highly characterized human 
embryonic kidney cell line, HEK293T [29]. This 
cell line provides an excellent and simple model 
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system to test whether these three proteins 
can drive general, not cancer specific, tumor 
formation. This model system is also highly rel-
evant since the parental cells express very low 
levels of FGFR2 (can thus be used as a partial 
negative control) and the cells are highly trans-
fectable (for protein overexpression or shRNA-
mediated knockdown of proteins of interest). 
HEK293T cells with and without FGFR2 overex-
pression were used for shRNA knock down 
experiments. These cells were stably transfect-
ed with Grb2 shRNA (to give Grb2 knock down 
cells G2i and (parental) PG2i respectively) or 
Plcγ1 shRNA (to give Plcγ1 knock down cells Pγi 
and PPγi respectively). These two cell lines 
were also stably transfected with scrambled 
shRNA (Ci and PCi cells respectively) to provide 
control cell lines. The knock down efficiencies 
for both Grb2 and Plcγ1 are shown elsewhere 
[29]. The 6 cell lines were also stably transfect-
ed with an empty luciferase vector and treated 
with luciferin (luciferase enzyme substrate) to 
detect the efficiency of luciferase vector trans-
fection and select for comparable expression 
levels (Figure 1A and 1B).
1 × 106 cells/cell line were injected into female 
nude mice (5 mice/cell line) to monitor tumour 
development. Tumors were only observed in 
G2i, Ci and PG2i injected mice (Figure 1C and 
1D), G2i tumors in the absence of Grb2 pro-
gressed to excessive burden and the mice had 
to be euthanized at day 38. By monitoring lucif-
erase-based luminescence at multiple time 
points, we observed that G2i tumors were 
unique in their ability to develop fast and form 
secondary tumors (Figure 1E and 1F). Tumor 
weight and number of nodules/tumor were also 
dramatically higher in G2i cells compared to Ci 
cells with PG2i cells forming the smallest 
tumors with a limited number of nodules (Figure 
1G and 1H). These data clearly indicate that 
tumor formation and malignancy are depen-
dent on FGFR2 expression and are enhanced 
with Plcγ1 expression and Grb2 depletion.
Expression levels of FGFR2, Grb2 and Plcγ1 
are indicators of invasive potential in LUAD cell 
lines
In order to investigate whether the established 
model system is relevant to cancer progres-
sion, we stained a multi-tumor tissue microar-
ray (95 cases of 40 cancer types from 27 
organs) and a LUAD tissue array (102 cases) 
with FGFR2, Grb2 and Plcγ1 antibodies. We 
observed that FGFR2 and Plcγ1 staining inten-
sity is higher in LUAD compared to normal lung 
tissue (Figure 2A) while it is lower for Grb2. This 
was also validated by the results obtained from 
The Human Protein Atlas Database (human 
Protein Atlas databses http://www.proteinat-
las.org/) where Grb2 expression is minimal 
unlike FGFR2/Plcγ1 which are medium to high 
in lung cancer tissues.
Based on the above, and taking into consider-
ation that a LUAD mouse model fails to suc-
cessfully mimic metastatic human adenocarci-
noma [31], we decided to investigate the 
correlation of our protein markers with cancer 
progression at a cellular level. We screened for 
cell lines that express variable levels of FGFR2, 
Grb2 and Plcγ1 and hence provide adequate 
controls (Figure 2B and 2C). We found that 
three LUAD cell lines (HCC1793, HCC44 and 
HCC515; also referred to as 1793, 44 and 515 
respectively) show differential expression lev-
els of FGFR2, Grb2 and Plcγ1. HCC44 and 
HCC515 express lower levels of FGFR2 com-
pared to HCC1793. Grb2 expression was con-
siderably higher in HCC44 and HCC515 com-
pared to HCC1793. Plcγ1 appeared higher in 
HCC44 and, HCC1793 compared to HCC515, 
but after adjusting for loading (Figure 2C) the 
difference was not significant.
Figure 1. FGFR2, Grb2 and Plcγ1 expression trend regulates tumor formation in xenograft mouse model of HEK 
293T model cell lines. A, B. Efficiency of transfection of luciferase vector in the indicated cell lines was determined 
by treating the cells in a 12-well plate with luciferin and measuring the activity via IVIS imaging system. Results were 
validated by luciferase reporter assay to measure luciferase activity. C. Mice injected with the indicated cell lines 
were imaged and tumor growth identified (see red circles). G2i mice had an increased tumour burden and had to be 
euthanized at day 38 (D38). The other mice were sacrificed at day 60 (D60). D. Tumours were then resected and im-
aged to show the burden where the scale-bar represents 1 cm. E. IVIS system based luminescence was measured at 
the indicated time points to monitor tumour development. F. Relative luminescence was plotted against days post-
injection. The error bars represent the standard deviation of the mean. G, H. Tumor weight and number of nodules/
tumor were determined and averaged per group of mice.
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Cells were left unstimulated or stimulated with 
fibroblast growth factor 9 (FGF9) to detect the 
effects of FGFR2, Grb2 and Plcγ1 protein con-
centration and FGFR2 activation (as an addi-
tional control) on the cells’ migratory and inva-
sive potentials (Figure 2D-F). A wound healing 
assay was used to measure the migratory 
potential of HCC1793 (high FGFR2, high Plcγ1 
and low Grb2), HCC515 (lower FGFR2, lower 
Plcγ1 and higher Grb2) and HCC44 cell line that 
expresses negligible level of FGFR2 and high 
Grb2 level (Figure 2B-D). Predictably based on 
protein expression levels the percentage wound 
healing was significantly different in the basal 
non-stimulated state with HCC1793 having the 
highest migratory potential followed by HCC515 
with HCC44 having the lowest percentage of 
wound healing (Figure 2D). Because our previ-
ous observations on the effects of FGFR2/Grb2 
and Plcγ1 on oncogenesis had been made 
Figure 2. FGFR2, Grb2 and Plcγ1 expression regulate the invasive potential of LUAD cell lines. A. Patient TMAs 
(multi-organ and lung cancer TMAs) were stained with antibodies against the 3 markers and pictures were taken 
at 20× magnification to show the intensity of the staining. B. Lung adenocarcinoma cell lines were serum starved, 
left unstimulated or stimulated with FGF9 for 30 minutes then used in western blot analysis. The blots were probed 
with the indicated antibodies. C. Results obtained in densitometric analysis from 3 independent experiments (n = 
3) were averaged and then used to generate a bar graph. Error bars denote the standard deviation of the calcu-
lated mean. Statistical significance was determined by Student’s t-Test- with *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001. D. The wound healing experiment was carried out as explained in the Materials and Methods 
section. Results from 3 independent experiments (n = 3) were averaged. Error bars denote the standard deviation 
of the calculated mean. Statistical significance was determined by Student’s t-Test- with *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001. E, F. The invasion assay was carried out as explained in the Materials and Methods 
section. The number of cells that invaded to the lower chamber containing 1% serum was counted, averaged and 
normalized from 3 independent experiments to measure the invasive potential of the cell lines used. Error bars de-
note the standard deviation of the calculated mean. Statistical significance was determined by Student’s t-Test- with 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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Table 1. A-C Association of biomarkers with patient characteristics with (A) showing the Spearman 
Correlation
A
Spearman Correlation Coefficients, N = 150 
Prob > |r| under H0: Rho=0
Plcγ1 Grb2 FGFR2
Age3 0.01493 -0.05529 0.03636
0.8561 0.5016 0.6587
Tumor_Size_Principal_cm -0.08397 0.13915 0.01494
0.3070 0.0895 0.8561
B
Marker Covariate Levels n Mean Std Stderr Min Max Median q1 q3 p Value P value <0.05
FGFR2 ADJ N 94 3.95 0.48 0.05 3.05 5.05 3.88 3.62 4.24 0.504
Y 56 3.97 0.52 0.07 2.96 5.55 4.02 3.75 4.30 .
Agegrp_1 ≥ Median 75 4.01 0.51 0.06 3.05 5.55 3.93 3.70 4.28 0.476
< Median 75 3.91 0.48 0.06 2.96 4.90 3.95 3.57 4.26 .
Gender F 73 3.93 0.47 0.05 3.05 5.05 3.88 3.62 4.27 0.469
M 77 3.98 0.52 0.06 2.96 5.55 4.00 3.68 4.26 .
Tobacco History N 19 3.84 0.51 0.12 3.05 4.90 3.85 3.35 4.28 0.326
Y 131 3.97 0.49 0.04 2.96 5.55 3.95 3.68 4.26 .
race2_1 Non Caucasian 19 4.10 0.55 0.13 3.09 5.02 4.24 3.72 4.33 0.129
Caucasian 131 3.94 0.48 0.04 2.96 5.55 3.90 3.62 4.23 .
Grb2 ADJ N 94 7.96 0.66 0.07 3.28 9.16 8.05 7.74 8.23 0.522
Y 56 8.01 0.59 0.08 5.69 9.18 8.11 7.67 8.37 .
Agegrp_1 ≥ Median 75 8.00 0.45 0.05 6.47 9.16 8.07 7.72 8.22 0.597
< Median 75 7.95 0.79 0.09 3.28 9.18 8.05 7.74 8.42 .
Gender F 73 7.93 0.58 0.07 5.69 8.84 8.05 7.73 8.29 0.455
M 77 8.02 0.69 0.08 3.28 9.18 8.07 7.75 8.25 .
Tobacco History N 19 7.74 0.65 0.15 6.47 9.18 7.81 7.29 8.05 0.022 *
Y 131 8.01 0.63 0.06 3.28 9.16 8.09 7.75 8.29 . *
race2_1 Non Caucasian 19 7.76 1.22 0.28 3.28 9.18 8.05 7.55 8.34 0.588
Caucasian 131 8.01 0.50 0.04 5.69 9.16 8.07 7.75 8.27 .
Plcγ1 ADJ N 94 7.56 0.62 0.06 6.22 9.29 7.54 7.21 7.93 0.130
Y 56 7.64 0.86 0.11 3.81 9.02 7.80 7.37 8.12 .
Agegrp_1 ≥ Median 75 7.61 0.64 0.07 6.22 9.08 7.57 7.15 8.01 0.848
< Median 75 7.57 0.79 0.09 3.81 9.29 7.63 7.28 8.07 .
Gender F 73 7.58 0.73 0.09 3.81 9.02 7.58 7.31 7.98 0.937
M 77 7.60 0.71 0.08 6.20 9.29 7.65 7.21 8.08 .
Tobacco History N 19 7.67 0.73 0.17 6.22 8.99 7.82 7.11 8.09 0.508
Y 131 7.58 0.72 0.06 3.81 9.29 7.57 7.24 8.01 .
race2_1 Non Caucasian 19 7.75 0.74 0.17 6.43 9.29 7.90 7.11 8.07 0.343
Caucasian 131 7.57 0.71 0.06 3.81 9.08 7.57 7.24 8.01 .
C
Marker Covariate Levels n Mean Std Stderr Min Max Median q1 q3 p Value p Value<0.05
FGFR2 Final Stage IASLC I 82 3.94 0.45 0.05 3.02 5.05 3.89 3.67 4.24 0.850
II 38 3.96 0.57 0.09 2.96 4.96 3.91 3.39 4.37 .
III 30 4.00 0.50 0.09 3.14 5.55 3.98 3.70 4.24 .
Pathological N N0 101 3.97 0.49 0.05 2.96 5.05 3.95 3.67 4.28 0.862
N1 28 3.96 0.59 0.11 3.14 5.55 3.89 3.51 4.25 .
N2 21 3.89 0.38 0.08 3.14 4.52 3.94 3.59 4.16 .
T IASLC 1 T1 46 3.91 0.47 0.07 3.07 5.05 3.86 3.70 4.15 0.554
T2 74 3.95 0.46 0.05 3.02 4.94 3.97 3.62 4.28 .
T3 25 4.00 0.64 0.13 2.96 5.55 4.05 3.45 4.32 .
T4 5 4.16 0.35 0.16 3.70 4.56 4.07 4.02 4.45 .
Type of smoker Current 64 3.87 0.43 0.05 2.96 4.76 3.91 3.62 4.17 0.146
Former 67 4.07 0.53 0.06 3.14 5.55 3.97 3.74 4.45 .
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under basal cell conditions, this study is 
focused on the non-stimulated state. However, 
it is worth noting that upon stimulation, the dif-
ference in migratory potential between the dif-
ferent cell lines was minimal (FIgure 2D). The 
FGFR2 concentration in HCC1793 decreases 
upon stimulation (Figure 2B) which is likely to 
be the effect of rapid receptor processing/deg-
radation of the receptor in this cell line. 
A Matrigel invasion assay was performed where 
cells were incubated in serum-deprived culture 
media in the upper chamber with 1% serum 
containing media in the lower chamber. Again 
HCC1793 had the highest invasive potential fol-
lowed by HCC515 with HCC44 being the least 
invasive (Figure 2E and 2F). Therefore the inva-
sive potential of the cell lines mirrored their 
migratory ability.
FGFR2, Grb2 and Plcγ1 are prognostic mark-
ers in LUAD patients
To examine the relevance of our identified 
markers to LUAD progression and clinical out-
come, we utilized the “The Profiling of 
Resistance patterns and Oncogenic Signaling 
Pathways in Evaluation of Cancers of the Thorax 
(PROSPECT)” trial data set from the Department 
of Thoracic/Head and Neck Medical Oncology 
at MD Anderson Cancer Center. We analyzed 
the processed gene expression levels in 150 
surgically resected lung adenocarcinomas, 
stages I-III, to test whether FGFR2, Grb2 and 
Plcγ1 concentrations varied significantly be- 
tween patients. The primary objectives of the 
study were to correlate the biomarkers with 
patients’ characteristics (age, gender, tobacco 
history, type of smoker, race, tumor size, final 
stage in International Association for the Study 
of Lung Cancer (IASLC) database, adjuvant 
therapy, tumor (T) and node (N) pathological 
staging) and clinical outcomes (with respect to 
(overall survival (OS) and recurrence-free sur-
vival (RFS)). The Patient Characteristics for 
Entire Cohort (N = 150) and the general Kaplan-
Meier Survival Curves (overall (OS) and recur-
rence free survival (RFS)) are shown in 
Supplementary Figure 1A (for OS) and 1B (for 
RFS) and Supplementary Table 1 where the 
median follow-up for those who survived at 5 
years is 60 months, After investigating the 
association of the biomarkers with patient 
Never 19 3.84 0.51 0.12 3.05 4.90 3.85 3.35 4.28 .
Grb2 Final Stage IASLC I 82 7.95 0.50 0.05 6.47 9.03 8.00 7.69 8.19 0.226
II 38 7.97 0.99 0.16 3.28 9.18 8.11 7.72 8.46 .
III 30 8.07 0.36 0.07 7.15 8.84 8.13 7.79 8.27 .
Pathological N N0 101 7.99 0.49 0.05 6.47 9.18 8.04 7.72 8.25 0.562
N1 28 7.86 1.10 0.21 3.28 9.16 8.14 7.76 8.29 .
N2 21 8.07 0.41 0.09 7.15 8.84 8.16 7.79 8.28 .
T IASLC 1 T1 46 7.81 0.81 0.12 3.28 8.74 8.04 7.57 8.19 0.123
T2 74 8.01 0.58 0.07 5.69 9.16 8.04 7.73 8.46 .
T3 25 8.14 0.41 0.08 7.62 9.18 8.12 7.78 8.28 .
T4 5 8.21 0.24 0.11 7.86 8.53 8.18 8.17 8.30 .
Type of smoker Current 64 8.03 0.80 0.10 3.28 8.85 8.12 7.80 8.50 0.016 *
Former 67 7.99 0.42 0.05 6.55 9.16 8.04 7.70 8.23 . *
Never 19 7.74 0.65 0.15 6.47 9.18 7.81 7.29 8.05 . *
Plcγ1 Final Stage IASLC I 82 7.59 0.61 0.07 6.22 9.29 7.54 7.26 7.94 0.123
II 38 7.44 0.90 0.15 3.81 9.08 7.57 6.92 7.93 .
III 30 7.79 0.69 0.13 6.20 9.02 7.91 7.44 8.13 .
Pathological N N0 101 7.54 0.65 0.06 6.20 9.29 7.52 7.10 7.93 0.046 *
N1 28 7.56 0.93 0.18 3.81 8.86 7.67 7.26 8.06 . *
N2 21 7.88 0.68 0.15 6.21 9.02 8.01 7.50 8.13 . *
T IASLC 1 T1 46 7.58 0.66 0.10 6.22 9.29 7.52 7.07 8.01 0.517
T2 74 7.64 0.75 0.09 3.81 9.02 7.73 7.37 8.01 .
T3 25 7.52 0.75 0.15 6.21 9.08 7.49 7.07 8.03 .
T4 5 7.35 0.69 0.31 6.20 8.08 7.49 7.44 7.52 .
Type of smoker Current 64 7.52 0.80 0.10 3.81 9.08 7.53 7.28 7.93 0.534
Former 67 7.64 0.63 0.08 6.40 9.29 7.70 7.15 8.09 .
Never 19 7.67 0.73 0.17 6.22 8.99 7.82 7.11 8.09 .
*Cutoff point determined by Martingale residual. 
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Table 2. Association of biomarkers with RFS
A
For Entire Cohort Excluding each outlier
Variable HR (95% CI) P-value HR (95% CI) P-value
Plcγ1 Per 1 unit increase 1.166 (0.774, 1.758) 0.4627 1.095 (0.695, 1.725) 0.6964
Grb2 Per 1 unit increase 0.937 (0.562, 1.564) 0.8044 0.936 (0.560, 1.564) 0.8003
FGFR2 Per 1 unit increase 0.892 (0.501, 1.585) 0.6958 0.798 (0.440, 1.447) 0.4576
Plcγ1 > Median vs. ≤ 7.6035 1.449 (0.799, 2.628) 0.2223 1.416 (0.781, 2.566) 0.2519
Grb2 > Median vs. ≤ 8.0675 0.597 (0.345, 1.031) 0.0641 0.596 (0.345, 1.031) 0.0640
FGFR2 > Median vs. ≤ 3.94 1.024 (0.585, 1.791) 0.9336 0.992 (0.564, 1.742) 0.9763
Plcγ1 > 7.58 vs. ≤ 7.58 1.556 (0.855, 2.834) 0.1479 1.520 (0.835, 2.766) 0.1708
Grb2 > 8.072 vs. ≤ 8.072 0.557 (0.321, 0.968) 0.0379 0.557 (0.321, 0.968) 0.0378
FGFR2 > 3.9955 vs. ≤ 3.9955 1.193 (0.684, 2.081) 0.5332 1.163 (0.664, 2.036) 0.5973
B
For Entire Cohort Excluding each outlier
Variable HR (95% CI) P-value HR (95% CI) P-value
Plcγ1 Per 1 unit increase 1.151 (0.767, 1.728) 0.4980 1.078 (0.687, 1.692) 0.7443
Grb2 Per 1 unit increase 0.935 (0.562, 1.556) 0.7957 0.933 (0.559, 1.556) 0.7903
FGFR2 Per 1 unit increase 0.924 (0.522, 1.634) 0.7848 0.823 (0.456, 1.485) 0.5171
Plcγ1 > Median vs. ≤ 7.6035 1.395 (0.773, 2.516) 0.2692 1.361 (0.755, 2.456) 0.3053
Grb2 > Median vs. ≤ 8.0675 0.612 (0.356, 1.052) 0.0759 0.612 (0.356, 1.052) 0.0758
FGFR2 > Median vs. ≤ 3.94 1.026 (0.590, 1.786) 0.9270 0.989 (0.565, 1.729) 0.9680
Plcγ1 > 7.58 vs. ≤ 7.58 1.494 (0.824, 2.706) 0.1859 1.457 (0.804, 2.640) 0.2143
Grb2 > 8.072 vs. ≤ 8.072 0.571 (0.331, 0.987) 0.0450 0.571 (0.331, 0.987) 0.0449
FGFR2 > 3.9955 vs. ≤ 3.9955 1.198 (0.690, 2.077) 0.5210 1.161 (0.666, 2.023) 0.5980
C
For Entire Cohort Excluding outliers
Variable HR (95% CI) P-value HR (95% CI) P-value
Plcγ1 > 7.58 vs. ≤ 7.58 1.497 (0.814, 2.754) 0.1940 1.427 (0.773, 2.634) 0.2551
Grb2 > 8.072 vs. ≤ 8.072 0.574 (0.330, 1.000) 0.0499 0.580 (0.333, 1.012) 0.0552
FGFR2 > 3.9955 vs. ≤ 3.9955 1.222 (0.698, 2.139) 0.4833 1.209 (0.690, 2.121) 0.5072
For Entire Cohort Excluding outliers
HR (95% CI) P-value HR (95% CI) P-value
Level of Composite variable2 0.01531 0.02241
Plcγ1 Low, FGFR2 Low, Grb2 High Reference Reference
Plcγ1 High, FGFR2 High, Grb2 Low 9.297 (1.992, 43.404) 0.0046 8.781 (1.866, 41.312) 0.0060
Other3 5.271 (1.250, 22.223) 0.0236 5.563 (1.317, 23.506) 0.0196
D
For Entire Cohort Excluding outliers
Variable HR (95% CI) P-value HR (95% CI) P-value
Plcγ1 > 7.58 vs. ≤ 7.58 1.426 (0.781, 2.604) 0.2485 1.360 (0.742, 2.495) 0.3201
Grb2 > 8.072 vs. ≤ 8.072 0.586 (0.338, 1.016) 0.0571 0.590 (0.340, 1.026) 0.0617
FGFR2 > 3.9955 vs. ≤ 3.9955 1.226 (0.706, 2.129) 0.4704 1.202 (0.690, 2.093) 0.5162
For Entire Cohort Excluding outliers
HR (95% CI) P-value HR (95% CI) P-value
Level Composite variable 0.01941 0.02931
Plcγ1 Low, FGFR2 Low, Grb2 High Reference Reference
Plcγ1 High, FGFR2 High, Grb2 Low 8.528 (1.856, 39.193) 0.0059 7.986 (1.721, 37.069) 0.0080
Other 5.044 (1.200, 21.209) 0.0272 5.290 (1.257, 22.260) 0.0231
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Figure 3. Independent gene expression of FGFR2, Grb2 and Plcγ1 correlate with patient survival. (A, B) Median was 
used as a cut-off point in the first Kaplan-Meier Recurrence-Free Survival curve (A. Log rank test P-value = 0.4897) 
A. Association of each Biomarker with RFS in Multivariable Cox adjusting for age group, gender, tumor size group, final Stage 
IASLC, and adjuvant therapy. B. Association of each Biomarker with RFS in Multivariable Cox Model adjusting for tumor size 
group. final stage IASLC. and adjuvant therapy. C. Association of three Biomarkers with RFS in Multivariable Cox Model Adjust-
ing for age group, gender, tumor size group, final stage IASLC, and adjuvant therapy. Upper panel: 3 biomarkers in the model. 
Lower panel: one composite variable to represent combinations of 3 biomarkers. 1P-value for overall effect. 2Composite vari-
able has 8 possible responses (each of three markers have 2 levels (high/low); low/low/low, low/low/high, low/high/low, low/
high/high, high/low/low, high/low/high, high/high/low, high/high/high). 3other combinations of biomarkers. D. Association of 
three Biomarkers with RFS in Multivariable Cox Model adjusting for tumor size group, final Stage IASLC, and adjuvant therapy. 
Upper panel: 3 biomarkers in the model. Lower panel: one composite variable to represent combinations of 3 biomarkers. 1P-
value for overall effect. 
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characteristics in Table 1 (Spearman correla-
tion is shown in Table 1A) and distribution of 
biomarkers across the entire cohort before and 
after excluding outlying measurements 
(Supplementary Table 2), we made two obser-
vations: 1) the Grb2 level is considerably higher 
in patients with smoking history with P = 0.022 
Table 1B). Significant differences in Grb2 is 
detected among three types of smokers (cur-
rent, former, never) with P = 0.016 (Table 1C). 
Current and former smokers have higher Grb2 
levels than never smokers, 2) Higher pathologi-
cal N is associated with higher Plcγ1 (P = 
0.046) (Table 1C). 
Next we investigated the association of the bio-
markers with RFS for univariate analysis of RFS 
(Supplementary Table 3A) and for multivariable 
Grb2 group (Table 2A). The Grb2 group (> 8.072 
vs. ≤ 8.072) showed significant association 
with RFS in all patients, adjusting for tumor size 
group, overall tumor stage and adjuvant thera-
py (Table 2B). The association remained signifi-
cant after excluding one patient with outlying 
measurement of Grb2. The high Grb2 group 
showed lower hazard of recurrence compared 
to the low Grb2 group (Table 2B). After includ-
ing all three markers and covariates in the mul-
tivariable model, we noticed that, after adjust-
ing for age group, gender, tumor size group, 
final stage IASLC, and adjuvant therapy, the 
Plcγ1 and FGFR2 groups were not significant 
but the Grb2 group was significant (P = 0.0499) 
(Table 2C upper panel). The Plcγ1 group, the 
Grb2 group and the FGFR2 group were not sig-
nificant when tumor size group, final stage 
and cut-off by recursive partitioning for the second graph (B. Log rank test P-value = 0.2063). (C, D) Median was 
used as a cut-off point in the first Kaplan-Meier Recurrence-Free Survival curve (C. Log rank test P-value = 0.1636) 
and cut-off by recursive partitioning for the second graph (D. Log rank test P-value = 0.1114). (E, F) Median was 
used as a cut-off point in the first Kaplan-Meier Recurrence-Free Survival curve (E. Log rank test P-value = 0.0294) 
and cut-off by recursive partitioning for the second graph (F. Log rank test P-value = 0.0165).
Figure 4. Combinatorial expression level of FGFR2, Grb2 and Plcγ1 correlate 
with patient survival. (A, B) For each marker, a cut-off of low/high was deter-
mined by recursive partitioning using RFS for (A) and OS for (B) as described 
in the Materials and Methods section.
model with clino-pathological/
reduced clino-pathological 
factors (Supplementary Table 
3B and 3C). In these cases 
the 5-year recurrence status 
was 55 (36.67%) with recur-
rence vs. 95 (63.33%) without 
recurrence. Six of the patients 
without recurrence at 5 years 
had recurrence in the subse-
quent 5 years. After looking at 
each marker and covariates in 
the multivariable model, we 
noticed that the Grb2 group (> 
8.072 vs. ≤ 8.072) showed 
significant association with 
RFS in all patients, adjusting 
for age group, gender, tumor 
size group, overall tumor 
stage and adjuvant therapy 
(HR (95% CI), 0.557 (0.321. 
0.968); P = 0.0379) (Table 
2A). The association remained 
significant after excluding one 
patient with outlying measure-
ment of Grb2 (HR (95% CI), 
0.557 (0.321. 0.968); P = 
0.0378). The high Grb2 group 
showed lower hazard of recur-
rence compared to the low 
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IASLC, and adjuvant therapy were adjusted 
(Table 2C upper panel). A composite variable 
representing combinations of three biomarkers 
with 3 levels (Plcγ1, FGFR2, Grb2 being low, 
low, high (27 patients) versus high, high, low 
(14 patients) versus the rest of combinations), 
and after adjusting for age group, gender, tumor 
size group, final stage IASLC, and adjuvant ther-
apy, showed significant differences between 
relative concentrations of Plcγ1 high, FGFR2 
high, Grb2 low and Plcγ1 low, FGFR2 low, Grb2 
high. The same result was obtained when com-
paring other combinations with Plcγ1 low, 
FGFR2 low, Grb2 high (Table 2C lower panel). 
The same significant associations were 
observed following the adjustment for multiple 
characteristics (tumour size, final stage IASCLC 
and adjuvant therapy) in different combinations 
like the one shown in Table 2D (upper and lower 
panel) before and after excluding patients with 
outlying measurements. As an additional con-
trol, we looked at the association of the bio-
markers with OS (Supplementary Table 4) 
where the median follow-up of surviving 
patients is 60 months. 5 year survival status 
was 52 (34.67%) deceased versus 98 (65.33%) 
alive. Nine patients in the “alive group” were 
deceased after 5 years. In this case the bio-
markers did not show significant association 
with survival even after adjusting for patient 
characteristics. Kaplan-Meier-RFC curves for 
each marker (with median as cut-off point or 
cut-off performed by recursive partitioning) are 
shown in Figure 3. In order to clearly depict the 
correlation of the combinatorial expression 
level of the markers with RFS in LUAD patients, 
we plotted 2 Kaplan-Meier curves for all mark-
ers in Figure 4A (percent without recurrence) 
and 4B (percent survived). In both cases it is 
clear that patients with FGFR2/Plcγ1/Grb2 rel-
ative concentrations as: high/high/low have 
the poorest prognosis whilst those having 
FGFR2/Plcγ1/Grb2 as: low/low/high drastically 
enhances the prognosis.
Discussion
Lung cancer, and specifically LUAD remain the 
main cause of cancer-related death in the 
world. This stems from the late stage diagnosis 
and the lack of personalized therapies limiting 
the treatment options to the existing palliative 
ones. FGFR2 signalling-related LUAD progres-
sion is specific to a subset of patients and even 
though the current design of FGFR2 targeting 
drugs seems promising, the challenge remains 
in identifying the patients that will benefit from 
such a treatment [32, 33]. Hence, appropriate 
selection and classification of patients is criti-
cal in minimizing drug toxicity and/or unneces-
sary administration of an irrelevant drug. 
Although aberrant activation of FGFR2 has 
been revealed as a novel driver in LUAD [7, 34, 
35], there has been no study that factors in 
other proteins associated with FGFR2-mediated 
signalling. Such a study is critical since we have 
shown that mutations and/or amplification of 
FGFR2 are not the sole drivers of oncogenic 
FGFR2 signalling [29, 30]. 
Our study, which is based on a xenograft mouse 
model, cell lines and accumulated clinical data, 
identifies FGFR2, Grb2 and Plcγ1 as novel prog-
nostic markers that will allow for a better under-
standing of patients’ profiles to determine the 
group that will benefit from an FGFR2-based 
treatment regimen while sparing the others 
from the negative side effects. Based on the 
relative protein concentrations dictating wheth-
er Plcγ1 can bind to FGFR2 and become acti-
vated, it defines patients with relative concen-
trations of FGFR2/Plcγ1/Grb2: high/high/low 
(HHL cases) as having the poorest prognosis 
while patients with FGFR2/Plcγ1/Grb2: low/
low/high (LLH cases) as having a more favour-
able one. As a result drugs that aim to inhibit 
FGFR2 kinase activity or modulate its expres-
sion might not be successful in treating HHL 
cases unless Plcγ1 and Grb2 are also thera-
peutically targeted. In HHL cases, inhibiting 
Plcγ1 binding to FGFR2 might be sufficient to 
maintain homeostasis and inhibit disease pro-
gression. This study introduces a combinatorial 
protein prognostic marker for LUAD raising the 
exciting prospect of a novel approach to deter-
mining patient outcomes.
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Supplementary Figure 1. Kaplan-Meier Survival Curves. A. OS, median follow-up for those who survived at 5 years 
is 60 months. B. Recurrence free survival (RFS).
Supplementary Table 1. Patient characteristics for entire cohort (N = 150)
Variable n Mean SD, Median (Minimum, Maximum)
Age (in year) 150 64.92 ± 10.33, 64.91 (40.99, 85.86)
Tumor Size Principal (cm) 150 3.8 ± 2.07, 3.35 (1, 14)
Category Frequency (%)
5-year Survival Death 52 (34.7%)
Survived 98 (65.3%)
5-year Recurrence Recurrence 55 (36.7%)
Without Recurrence 95 (63.3%)
Gender Male 77 (51.3%)
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Female 73 (48.7%)
Age Group < 65 years 75 (50.0%)
≥ 65 years 75 (50.0%)
Race African American 8 (5.3%)
Asian 6 (4.0%)
Caucasian 131 (87.3%)
Hispanic 5 (3.3%)
Tobacco History No 19 (12.7%)
Yes 131 (87.3%)
Type of smoker Current 64 (42.7%)
Former 67 (44.7%)
Never 19 (12.7%)
Final Stage IASLC I 82 (54.7%)
II 38 (25.3%)
III 30 (20%)
T IASLC 1 T1 46 (30.7%)
T2 74 (49.3%)
T3 25 (16.7%)
T4 5 (3.3%)
Pathological N N0 101 (67.3%)
N1 28 (18.7%)
N2 21 (14%)
KRAS MUT1 Mutant 36 (25%)
WT 108 (75%)
EGFR MUT2 Mutant 21 (15.2%)
WT 117 (84.8%)
ADJ No 94 (62.7%)
Yes 56 (37.3%)
1Frequency missing = 6. 2Frequency missing = 12.
Supplementary Table 2. Distributions of biomarkers for Entire Cohort (N = 150)
A
Variable n Mean SD, Median (Minimum, Maximum)
Plcγ1 150 7.59 ± 0.72, 7.60 (3.81, 9.29)
Grb2 150 7.98 ± 0.64, 8.07 (3.28, 9.18)
FGFR2 150 3.96 ± 0.49, 3.94 (2.96, 5.55)
B
Variable n Mean SD, Median (Minimum, Maximum)
Plcγ1 149 7.62 ± 0.65, 7.63 (6.20, 9.29)
Grb2 149 8.01 ± 0.51, 8.07 (5.69, 9.18)
FGFR2 149 3.95 ± 0.48, 3.94 (2.96, 5.05)
A. All Measurements. B. Excluding outlying Measurements.
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Supplementary Table 3. Association of biomarkers with Recurrence-free Survival (RFS)
A
Variable HR (95% CI) P-value
Age (in year) Per Year increase 1.0138 (0.9870, 1.0414) 0.3162
Age Group > Median vs. ≤ 64.91 1.2719 (0.7478, 2.1633) 0.3748
Gender Male vs. Female 1.1425 (0.6732, 1.9390) 0.6215
Race Caucasian vs. Others 0.7875 (0.3854, 1.6093) 0.5124
Tobacco History Yes vs. No 0.8517 (0.4024, 1.8025) 0.6747
Tumor Size Group1 > 2.7* cm vs. ≤ 2.7 2.1499 (1.1709, 3.9473) 0.0136
Tumor Size Group2 > Median vs. ≤ 3.35 2.1463 (1.2623, 3.6494) 0.0048
KRAS Mutation1 Yes vs. No 0.9367 (0.4999, 1.7550) 0.8383
EGFR Mutation2 Yes vs. No 1.1428 (0.5525, 2.3639) 0.7189
Adjuvant Yes vs. No 0.7218 (0.4235, 1.2302) 0.2307
Plcγ1 Per 1 unit increase 1.3426 (0.9082, 1.9848) 0.1396
Grb2 Per 1 unit increase 1.0261 (0.6228, 1.6905) 0.9194
FGFR2 Per 1 unit increase 1.0784 (0.6234, 1.8655) 0.7872
Plcγ1 > Median vs. ≤ 7.6035 1.8253 (1.0534, 3.1627) 0.0319
Grb2 > Median vs. ≤ 8.0675 0.6847 (0.4005, 1.1704) 0.1661
FGFR2 > Median vs. ≤ 3.94 1.2055 (0.7089, 2.0501) 0.4903
Plcγ1 > 7.583 vs. ≤7 .58 1.9499 (1.1180, 3.4007) 0.0186
Grb2 > 8.0723 vs. ≤ 8.072 0.6472 (0.3771, 1.1105) 0.1142
FGFR2 > 3.99553 vs. ≤ 3.9955 1.4048 (0.8271, 2.3858) 0.2085
Final Stage IASLC 0.00114
II vs. I 1.5514 (0.7980, 3.0162) 0.1954
III vs. I 3.2123 (1.7299, 5.9651) 0.0002
Pathological N 0.02904
N1 vs. N0 1.7337 (0.8899, 3.3776) 0.1059
N2 vs. N0 2.3282 (1.1938, 4.5403) 0.0131
T IASLC 0.00874
T2 vs. T1 1.1738 (0.6155, 2.2385) 0.6266
T3 vs. T1 2.7887 (1.3220, 5.8828) 0.0071
T4 vs. T1 3.9913 (1.1534, 13.8115) 0.0289
Type of smoker 0.90564
Current vs. Never 0.8329 (0.3725, 1.8624) 0.6561
Former vs. Never 0.8704 (0.3910, 1.9377) 0.7340
B
Variable HR (95% CI) P-value
Age Group > Median vs. ≤ 64.91 1.407 (0.802, 2.469) 0.2340
Gender Male vs. Female 0.900 (0.516, 1.569) 0.7093
Tumor Size Group2 > Median vs. ≤ 3.35 1.890 (1.052, 3.396) 0.0333
Final Stage IASLC 0.0014
II vs. I 1.376 (0.696, 2.721) 0.3585
III vs. I 3.952 (1.876, 8.323) 0.0003
Adjuvant Yes vs. No 0.762 (0.383, 1.517) 0.4391
C
Variable HR (95% CI) P-value
Tumor Size Group2 > Median vs. ≤ 3.35 1.890 (1.052, 3.396) 0.0333
Final Stage IASLC 0.0014
II vs. I 1.376 (0.696, 2.721) 0.3585
III vs. I 3.952 (1.876, 8.323) 0.0003
Adjuvant Yes vs. No 0.762 (0.383, 1.517) 0.4391
5-year recurrence status: 55 (36.67%) with recurrence vs. 95 (63.33%) without recurrence (6 patients without recurrence at 5 
years had recurrence after 5 years). A. Univariate analysis of RFS. *Cutoff point determined by Martingale residual. 1Frequency 
missing = 6. 2Frequency missing = 12. 3Cutoff point determined by recursive partitioning (rpart function in R, First knot) using 
RFS. 4P-value for overall effects. B. Multivariable Model with Clinicopathological Factors. C. Multivariable Model with reduced 
Clinicopathological Factors.
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Supplementary Table 4. Association of biomarkers with OS where median follow-up of surviving 
patients is 60 months
A
Variable HR (95% CI) P-value
Age (in year) Per 1 Year increase 1.0297 (1.0010, 1.0593) 0.0425
Age Group > Median vs. ≤ Median 1.3821 (0.7994, 2.3894) 0.2466
Gender Male vs. Female 1.6285 (0.9356, 2.8347) 0.0846
Race Caucasian vs. Others 1.5984 (0.6354, 4.0207) 0.3190
Tobacco History Yes vs. No 1.2213 (0.5213, 2.8611) 0.6453
Tumor Size Group 1 > 2.7 cm vs. ≤ 2.7 3.6306 (1.7084, 7.7155) 0.0008
Tumor Size Group 2 > 3.5cm vs. ≤ 3.5  2.4753 (1.4214, 4.3106) 0.0014
KRAS Mutation1 Yes vs. No 0.7889 (0.4039, 1.5411) 0.4877
EGFR Mutation2 Yes vs. No 0.4487 (0.1608, 1.2519) 0.1258
Adjuvant Therapy Yes vs. No 1.1493 (0.6604, 2.0001) 0.6225
Plcγ1 Per 1 unit increase 1.2611 (0.8469, 1.8779) 0.2534
Grb2 Per 1 unit increase 0.9821 (0.6321, 1.5258) 0.9358
FGFR2 Per 1 unit increase 0.7193 (0.4142, 1.2492) 0.2420
Plcγ1 > Median vs. ≤ 7.6035 1.4075 (0.8114, 2.4415) 0.2239
Grb2 > Median vs. ≤ 8.0675 1.0157 (0.5896, 1.7496) 0.9554
FGFR2 > Median vs. ≤ 3.94 0.8293 (0.4806, 1.4311) 0.5014
Plcγ1 > 7.583 vs. ≤ 7.58 1.3590 (0.7835, 2.3573) 0.2750
Grb2 > 8.0723 vs. ≤ 8.072 0.9575 (0.5556, 1.6502) 0.8758
FGFR2 > 3.99553 vs. ≤ 3.9955 0.8668 (0.4999, 1.5030) 0.6108
Final Stage IASLC <0.00014
II vs. I 2.3131 (1.1686, 4.5783) 0.0161
III vs. I 4.7286 (2.4244, 9.2227) 0.0000
Pathological N 0.00374
N1 vs. N0 2.1027 (1.0978, 4.0276) 0.0250
N2 vs. N0 2.9451 (1.4834, 5.8472) 0.0020
T IASLC 0.00024
T2 vs. T1 1.3791 (0.6686, 2.8446) 0.3842
T3 vs. T1 3.5118 (1.6105, 7.6576) 0.0016
T4 vs. T1 7.8358 (2.4778, 24.7795 0.0005
Type of smoker 0.89764
Current vs. Never 1.2331 (0.5019, 3.0295) 0.6478
Former vs. Never 1.2097 (0.4922, 2.9730) 0.6782
B
Variable HR (95% CI) P-value
Age Group > Median vs. ≤ Median 1.550 (0.877, 2.738) 0.1313
Gender Male vs. Female 1.207 (0.677, 2.150) 0.5232
Tumor Size Group 2 > Median vs. ≤ Median 2.119 (1.159, 3.876) 0.0148
Final Stage IASLC <0.00011
II vs. I 1.929 (0.954, 3.903) 0.0676
III vs. I 6.480 (3.013, 13.937) <.0001
Adjuvant Yes vs. No 0.537 (0.277, 1.040) 0.0653
C
Variable HR (95% CI) P-value
Tumor Size Group 2 > Median vs. ≤ Median 2.012 (1.119, 3.617) 0.0194
Final Stage IASLC <0.00011
II vs. I 6.637 (3.111, 14.160) <.0001
III vs. I 1.928 (0.951, 3.907) 0.0685
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Adjuvant Yes vs. No 0.511 (0.264, 0.986) 0.0454
D
For Entire Cohort Excluding each outlier
Variable HR (95% CI) P-value HR (95% CI) P-value
Plcγ1 Per 1 unit increase 1.110 (0.725, 1.699) 0.6309 1.060 (0.670, 1.679) 0.8031
Grb2 Per 1 unit increase 0.849 (0.545, 1.323) 0.4700 1.124 (0.629, 2.008) 0.6931
FGFR2 Per 1 unit increase 0.620 (0.352, 1.094) 0.0989 0.549 (0.307, 0.983) 0.0437
Plcγ1 > Median vs. ≤ 7.6035 1.133 (0.630, 2.040) 0.6763 1.117 (0.621, 2.011) 0.7119
Grb2 > Median vs. ≤ 8.0675 0.876 (0.501, 1.530) 0.6409 0.908 (0.517, 1.595) 0.7379
FGFR2 > Median vs. ≤ 3.94 0.698 (0.393, 1.241) 0.2206 0.670 (0.375, 1.198) 0.1770
Plcγ1 > 7.58 vs. ≤ 7.58 1.073 (0.599, 1.923) 0.8117 1.057 (0.590, 1.894) 0.8529
Grb2 > 8.072 vs. ≤ 8.072 0.817 (0.467, 1.428) 0.4772 0.845 (0.481, 1.485) 0.5579
FGFR2 > 3.9955 vs. ≤ 3.9955 0.718 (0.401, 1.285) 0.2645 0.691 (0.383, 1.245) 0.2181
E
For Entire Cohort Excluding each outlier
Variable HR (95% CI) P-value HR (95% CI) P-value
Plcγ1 Per 1 unit increase 1.124 (0.742, 1.704) 0.5802 1.063 (0.674, 1.676) 0.7930
Grb2 Per 1 unit increase 0.887 (0.572, 1.373) 0.5898 1.162 (0.653, 2.068) 0.6095
FGFR2 Per 1 unit increase 0.675 (0.388, 1.172) 0.1627 0.594 (0.337, 1.048) 0.0720
Plcγ1 > Median vs. ≤ 7.6035 1.159 (0.648, 2.072) 0.6192 1.135 (0.634, 2.031) 0.6692
Grb2 > Median vs. ≤ 8.0675 0.935 (0.541, 1.616) 0.8096 0.972 (0.559, 1.689) 0.9199
FGFR2 > Median vs. ≤3.94 0.729 (0.413, 1.284) 0.2737 0.695 (0.392, 1.233) 0.2138
Plcγ1 > 7.583 vs. ≤ 7.58 1.078 (0.606, 1.918) 0.7988 1.055 (0.592, 1.879) 0.8566
Grb2 > 8.0723 vs. ≤ 8.072 0.872 (0.504, 1.507) 0.6231 0.904 (0.520, 1.572) 0.7213
FGFR2 > 3.99553 vs. ≤ 3.9955 0.753 (0.425, 1.336) 0.3324 0.720 (0.403, 1.287) 0.2678
F
For Entire Cohort Excluding outliers
Variable HR (95% CI) P-value HR (95% CI) P-value
Plcγ1  > 7.58 vs. ≤ 7.58 1.077 (0.599, 1.935) 0.8052 1.008 (0.554, 1.833) 0.9797
Grb2 > 8.072 vs. ≤ 8.072 0.837 (0.476, 1.472) 0.5372 0.883 (0.496, 1.569) 0.6704
FGFR2 > 3.9955 vs. ≤ 3.9955 0.726 (0.405, 1.300) 0.2808 0.719 (0.397, 1.302) 0.2758
G
For Entire Cohort Excluding outliers
HR (95% CI) P-value HR (95% CI) P-value
Level of Composite variale 0.78171 0.79461
Plcγ1 Low, FGFR2 Low, Grb2 High Reference Reference
Plcγ1 High, FGFR2 High, Grb2 Low 1.456 (0.459, 4.619) 0.5236 1.306 (0.396, 4.304) 0.6607
Other 1.350 (0.549, 3.317) 0.5129 1.366 (0.554, 3.368) 0.4979
H
For Entire Cohort Excluding outliers
Variable HR (95% CI) P-value HR (95% CI) P-value
Plcγ1  >7.58 vs. ≤7.58 1.087 (0.609, 1.942) 0.7776 1.013 (0.560, 1.833) 0.9650
Grb2 >8.072 vs. ≤8.072 0.897 (0.516, 1.560) 0.7002 0.941 (0.535, 1.656) 0.8342
FGFR2 >3.9955 vs. ≤3.9955 0.758 (0.426, 1.348) 0.3451 0.747 (0.415, 1.343) 0.3295
I
For Entire Cohort Excluding outliers
HR (95% CI) P-value HR (95% CI) P-value
Level of Composite variale 0.75601 0.79941
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Plcγ1 Low, FGFR2 Low, Grb2 High Reference Reference
Plcγ1 High, FGFR2 High, Grb2 Low 1.513 (0.492, 4.657) 0.4702 1.329 (0.415, 4.252) 0.6319
Other 1.339 (0.546, 3.282) 0.5234 1.358 (0.553, 3.338) 0.5047
5-year survival status: 52 (34.67%) deceased vs. 98 (65.33%) alive (9 patients in alive group were deceased after 5 years). A. 
Univariate analysis of OS.1Frequency missing = 6. 2 Frequency missing = 12. 3Cutoff point determined by recursive partitioning 
(rpart function in R, First knot) using RFS. 4P-value for overall effects. B. Multivariable Model with clinicopathological Factors 
1P-value for overall effects. C. Multivariable Model with significant clinicopathological Factors. 1P-value for overall effects. D. 
Association of each biomarker with OS in Multivariable Cox Model adjusting for age group, gender, tumor size group, final stage 
IASLC, and adjuvant therapy. E. Association of each biomarker with OS in Multivariable Cox Model adjusting for tumor size 
group, final stage IASLC, and adjuvant therapy. F. Association of 3 biomarkers with OS in Multivariable Cox Model adjusting 
for age group, gender, tumor size group, final Stage IASLC, and adjuvant therapy (all 3 markers were included in the same 
multivariable model. Correlations between pair of 3 markers were not significant). Upper panel: Three biomarkers in the model. 
Lower panel: Composite variable to represent combinations of three biomarkers. G. Association of 3 biomarkers with OS in 
Multivariable Cox Model adjusting for tumor size group, final stage IASLC, and adjuvant (all three markers were included in the 
same multivariable model). Upper panel: 3 biomarkers in the model. Lower panel: Composite variable to represent combina-
tions of three biomarkers. 1P-value for overall effect. H, I. Association of 3 biomarkers with OS in Multivariable Cox Model ad-
justing for tumor size group, final stage IASLC, and adjuvant (all three markers were included in the same multivariable model). 
H. 3 biomarkers in the model. I. Composite variable to represent combinations of three biomarkers. 1P-value for overall effect.
